icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
7h0Zn2F8a1Jq1TtS